Frontlight ResearchEarly access
Active, not recruitingPhase 2/3
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
Key facts
- Who runs it
- AO GENERIUM
- Where
- Russia5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 32 people, planned
- Started
- 30 Nov 2021
- Expected to end
- Mar 2028
- Type of study
- Interventional, 3 groups
- Treatments tested
- GNR-055 1.0-2.0-3.0 mg/kg
- GNR-055 2.0 mg/kg
- GNR-055 3.0 mg/kg
- Record updated
- 21 September 2026
Who can take part
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Signed inform consent
- Verified diagnosis of MPS II (Hunter syndrome)
- Naïve patients or patients who have received standard ERT whit idursulfase products
- No contraindications for lumbar puncture as judged by the Investigator
- Willingness and ability to follow study procedures
Who cannot take part
- Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study
- Clinically pronounced hypersensitivity to ID2S or any other component of the drug product
- History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation
- Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
The 3 groups in the trial
- Adult: GNR-055Treatment being tested
GNR-055: 1.0-2.0-3.0 mg/kg
Treatment: GNR-055 1.0-2.0-3.0 mg/kg
- Paediatric: GNR-055 2.0 mg/kgTreatment being tested
GNR-055 2.0 mg/kg
Treatment: GNR-055 2.0 mg/kg
- Paediatric: GNR-055 3.0 mg/kgTreatment being tested
GNR-055 3.0 mg/kg
Treatment: GNR-055 3.0 mg/kg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC "GENERIUM", Russia) in Patients With Mucopolysaccharidosis Type II
- Record updated
- 21 September 2026